Gedeon Richter Launches Pregabalin-Richter Medication
Hungarian pharmaceutical company Gedeon Richter Plc. has launched Pregabalin-Richter, a new medication containing the active substance pregabalin. The drug is indicated for the treatment of neuropathic pain, epilepsy, generalized anxiety disorder, and fibromyalgia in adults.
Gedeon Richter Plc., a multinational pharmaceutical company headquartered in Hungary, has introduced Pregabalin-Richter to the market. This medication contains pregabalin as its active ingredient and is prescribed for adults with conditions including neuropathic pain, epilepsy, generalized anxiety disorder, and fibromyalgia.
Neuropathic pain is a type of chronic pain resulting from damage to the nervous system, manifesting with symptoms such as burning sensations, shooting pains, tingling, or numbness. For epilepsy, Pregabalin-Richter is an add-on therapy for specific partial seizures in adults when other treatments have been insufficient.
Generalized anxiety disorder involves persistent, excessive, and difficult-to-control worry and anxiety, accompanied by symptoms like restlessness and fatigue. Fibromyalgia is characterized by widespread musculoskeletal pain, stiffness, depression, and sleep disturbances.
The mechanism of Pregabalin-Richter involves binding to specific proteins in the central nervous system, which is thought to contribute to its analgesic and anticonvulsant effects. The medication is intended solely for adult use and should be administered under the guidance of a healthcare professional.